In conclusion, we found that CSF Ng can be a useful early biomarker of AD-related impairment, although its role as an AD biomarker appears to diminish after dementia diagnosis, whereby the discriminatory value of Ng begins to decrease as the underlying processes related to disease progression in AD and FTLD begin to merge. Here, NRGN is linked to Alzheimer disease.